Consumer Marketing Briefs

Share this article:
Consumer Reports took a jab at Boniva ads starring Sally Field in an episode of its Adwatch online video series, which has previously tackled spots for Cialis, Rozerem, Requip and Chantix. Associate editor Jamie Hirsch concluded: “Bottom line—Sally's a great spokesperson and we do like her. But we think you should ask your doctor whether you really need such an expensive bisphosphonate.”

DDMAC is adding a third review group for consumer promotions to keep up with surging submissions. The third group will be led by Sangeeta Vaswani, previously acting leader for Professional Review Group III, according to Marci Keister, who heads DTC Review Group II.  

Reps. James Moran (D-VA) and Robert Brady (D-PA) introduced a bill, dubbed the “Families for ED Advertising Decency Act,” that would ban ED ads on radio or TV between the hours of 6:00 am and 10:00 pm —an edict that would comport, more or less, with existing guidelines of PhRMA and individual manufacturers. Moran contends that weekend daytime sporting events are nonetheless “saturated” with ED ads, and wants to empower the FCC to fine broadcasters that air them between those hours.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?